SUBSCRIBE
SUBSCRIBE
Tristan Manalac

Tristan Manalac

Contributing Writer | News

Tristan is an independent science writer based in Metro Manila, with more than eight years of experience writing about medicine, biotech and science. Being formally trained in molecular biology, he once dreamed of collecting degrees and starting his own lab. But these days, he finds his greatest joy in a bottle of beer and a beautiful sentence. He can be reached at tristan.manalac@biospace.com, tristan@tristanmanalac.com or on LinkedIn.

GSK's office in Dresden, Germany
Deals
GSK Pays $430M Upfront for CureVac’s COVID-19, Flu mRNA Vaccines
GSK on Wednesday restructured its contract with CureVac to gain access to the biotech’s influenza and COVID-19 programs for $430 million upfront and up to $1.13 billion in future payments.
July 3, 2024
 · 
2 min read
 · 
Tristan Manalac
U.S. and Chinese flags in concrete, broken in the middle
Policy
BIOSECURE Act Erodes Industry Confidence in Chinese Contractors: Report
Despite an uncertain legislative path to becoming law, the BIOSECURE Act has already impacted the biopharma industry’s confidence in Chinese service providers and prompted efforts to diversify manufacturing partners.
July 3, 2024
 · 
2 min read
 · 
Tristan Manalac
Eli Lilly's biotechnology center in California
Deals
Lilly Inks Radiopharma Deal With Radionetics, Secures Right to Buy Biotech
Eli Lilly is expanding its radiopharmaceutical portfolio with a $140 million upfront payment to Radionetics Oncology and the exclusive future right to acquire the biotech for $1 billion.
July 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Two workers in a sterile manufacturing facility
Deals
Samsung Bio Nabs $1B Manufacturing Contract With Undisclosed US Pharma
Samsung Biologics announced Tuesday it has signed its largest contract ever—a $1.06 billion manufacturing deal with an unnamed pharmaceutical company headquartered in the U.S.
July 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: U.S. Department of Justice building in Washington, DC
Policy
Two Senior Cassava Employees Subjects in Federal Probes After Former Advisor Indicted for Fraud
The Department of Justice and Securities and Exchange Commission are investigating two senior employees of Cassava Sciences in connection with allegations of data manipulation for its Alzheimer’s disease candidate simufilam.
July 2, 2024
 · 
2 min read
 · 
Tristan Manalac
Entrance of the FTC in Washington, DC
Policy
FTC Investigates Teva Over Refusal to Remove Improperly Listed Patents from Orange Book
The Federal Trade Commission has opened an investigation into Teva Pharmaceuticals after the company allegedly ignored directives to withdraw or amend contentious patent listings on the FDA’s Orange Book.
July 2, 2024
 · 
1 min read
 · 
Tristan Manalac
Business partners discussing the terms of a contract
Patents
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Infectious Disease
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
U.S. Supreme Court in Washington, DC
Policy
Supreme Court’s Chevron Doctrine Ruling Could Limit FDA’s Regulatory Authority
The U.S. Supreme Court on Friday overturned the long-standing Chevron doctrine, which required courts to defer to federal agencies and their interpretation of statutes, putting potential limits on the FDA’s regulatory decisions.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Antibody drug conjugates (ADCs) are targeted medicines that deliver chemotherapy agents to cancer cells 3d rendering
Business
Eisai Assumes Sole Responsibility for ADC After Collaboration With BMS Ends
Due to Bristol Myers Squibb’s ongoing portfolio reprioritization, Eisai is taking over the development and commercialization of farletuzumab ecteribulin, an investigational antibody-drug conjugate targeting solid tumors.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
The Legal Execution Department makes an appointment with the customer to sign a mediation agreement to pay the debt.
Policy
Daiichi Sankyo Wins $47M in ADC Patent Arbitration With Seagen, Pfizer Dispute Looms
Daiichi Sankyo has secured a victory in its patent arbitration with Seagen, nabbing a $47 million award for attorneys’ fees and other costs, plus interest. However, a larger patent battle with Pfizer remains.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Feb 2, 2020 South San Francisco / CA / USA - Merck & Co. headquarters in Silicon Valley; Merck & Co. Inc. is an American multinational pharmaceutical company
Policy
CDC Backs Merck’s Capvaxive, Tees Up Pneumococcal Competition With Pfizer
In a potential challenge to Pfizer’s Prevnar 20, Merck’s Capvaxive has been recommended by the Centers for Disease Control and Protection for use in preventing invasive pneumococcal disease in adults.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Supreme Court of the United States. Washington DC, USA.
Policy
Supreme Court’s Chevron Doctrine Ruling Could Limit FDA’s Regulatory Authority
The U.S. Supreme Court on Friday overturned the long-standing Chevron doctrine, which required courts to defer to federal agencies and their interpretation of statutes, putting potential limits on the FDA’s regulatory decisions.
July 1, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: Nasdaq building in New York City
Deals
Alumis Pushes Through With Smaller IPO, Looks to Raise $250M for Immuno Candidate
Alumis is debuting in an initial public offering Friday on the Nasdaq, though the $250 million IPO is less than its initial targeted raise of $274 million just days ago.
June 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Pictured: AbbVie's headquarters in California
Deals
AbbVie Expands Immuno Portfolio With $250M Celsius Buy as Humira Hits Patent Cliff
AbbVie on Thursday announced it has acquired Celsius Therapeutics to expand its immunology portfolio with a first-in-class TREM1 inhibitor CEL383, following other big players looking to cash in on the hot immuno market.
June 28, 2024
 · 
2 min read
 · 
Tristan Manalac
Load More